Enosium Life Science

🚀 Biotech Trailblazers: How First-Time Launchers Are Shaping Pharma’s Future Biotech innovators are rewriting the rules of pharmaceutical launches. First-time launchers, now responsible for 40% of new drugs since 2018, are poised to dominate the industry, with 80% of upcoming blockbuster drugs coming from their pipelines. But while their potential is immense, so are the challenges. Limited resources, high commercialization costs, and competitive markets mean that only 20-30% exceed expectations less than half the rate of established players. What sets the successful apart ? 🔑 Strategic Portfolio Management Focusing on rare diseases or under-served markets drives higher success rates. Companies with platform technologies and diversified pipelines stand out. 💡 Commercial Investment Top-performing launchers invest heavily—1.5x more than peers—in market education, access strategy, and promotional efforts. 📊 Data-Driven Precision Digital tools, from AI-guided outreach to analytics-driven marketing, enable smarter resource allocation and stronger market impact. 💰 Early Fundraising Securing capital before pivotal milestones ensures smoother commercialization, avoiding last-minute resource gaps. 🌍 Proactive Market Access Engaging payers early and building robust pricing strategies sets the stage for broader coverage and sustainable success. First-time launchers hold the potential to transform healthcare with breakthroughs in rare diseases and gene therapies. By embracing innovation and strategic planning, they’re not just competing they’re leading. 👉 At Enosium Life Science, we are committed to empowering life sciences companies as they navigate the challenges of drug launches. From market access strategy to medical affairs support, we help bring transformative therapies to patients more efficiently and effectively. McKinsey & Company Antoine Bassel Amer Stephane Roze Gabriel MARTIN Herve Lilliu France Biotech EuropaBio - the European Association for Bioindustries International Council of Biotechnology Associations (ICBA) https://lnkd.in/exCKBUJZ

At Enosium Life Science, we believe in blending work with passion, energy and fun. The teams from Vyoo Agency and Inbeeo, part of the Enosium Life Science Group, had the pleasure of reconnecting at #ISPOR24 ✨ Highlights of the event: 👉 An active and noteworthy participation 👉 Inspiring exchanges with access and HEOR experts from around the world 👉 Enhanced networking opportunities 👉 A dynamic and collaborative spirit we’re proud to share—and excited to renew in the future We’re already looking forward to the next opportunity to drive #innovation in #healthcare and #marketaccess in Europe together!

[Save the date]📆D-5 before ISPOR—The Professional Society for Health Economics and Outcomes Research Real World Evidence Summit 2024, taking place In Barcelona, from november 17th to 20th. 👉 An inspirational event that focuses on the science, practice, and policies of healthcare value assessment and promote a broader view of health economics and outcomes research (HEOR) that considers the physical, mental, and social health aspects of #innovation. 👉 an european event featuring Inbeeo and Vyoo Agency, part of Enosium Life Science group, for Inbeeo ✔️ a podium presentation November 19th at 1.45 pm : "Assessing the Impact of Access Policies on Biosimilar Pricing: A Comparative Study of Five Major European Markets" ✔️ a poster presentation November 19th at 10.30 pm : "Reimbursement Incentives for Antibiotics in Eleven European Countries: A Comparative Analysis" Vyoo agency, 5 poster presentations ✔️ November 18th at 10.30 am :"Cross analysis of Has Conclusions amongst Products with an economic Opinion posted in 2023" ✔️ November 19th at 10.30 am :"Level of ICER of Health Economic Assessment in France in 2023" and "Uncertainty Appraisal in Economic Opinions with the French National Authority of Health" ✔️ November 19th at 4.00 pm :"French Health Authority Appraisals of economic Evaluations in early stage" ✔️ November 20th at 9.00 am :"methodological Acceptability of the economic Analyses assessed by the HAS in 2023" 👉 Enosium’s market access and HEOR experts are attending and would be glad to meet you there. Inbeeo : Herve Lilliu, Enzo Straccia, Vishal Yadav, Tania Savant. Vyoo agency : Stephane Roze Julie Chevalier Bertrand Tehard

🌟 "Great successes are done by a team of talents" 🌟 At Enosium Life Science, we are passionnate about shaping the healthcare ecosystem in Europe and we are convinced that our people are the roots of every success. We are excited to recruit for several key positions to strengthen our team and accelerate our growth: 1. Head of Operations – A visionary leader to drive our operations and to create value with efficiency. Job description : https://lnkd.in/eVe2-uwA 2. Finance Manager – An expert to manage our financial strategy and operations and to contribute to our growth . Job description : https://lnkd.in/eSDGUzrh 3. Marketing & Communication Manager – A creative mind to develop our market presence and impact. Job description : https://lnkd.in/eUPZ-qVJ 4. Commercial Director – A commercial leader to propel our ambitions and to put our customers’ needs in everything we do. Job description : https://lnkd.in/e8nu8eth Are you passionate about life science services and consulting? Are you driven by results and performance? Do you believe that only sky's the limit for your ambition? Join us to make a remarkable impact on patients’ lives in Europe To apply for one of these opportunities or to ask for more information, please write to Laure, our talents acquisition partner:  LStorck@virdisgroup.com  #recruitment #innovation #lifeScience #careers #EnosiumLifeScience #leadership #opportunities Otium Basile Paul-Petit Maxime de Varine-Bohan Michael Sidney Levy Virdis Group Antoine Bassel Amer Thibault Wirth Gabriel MARTIN

🚀 This is the purpose of Enosium Life Science 💡 Bringing a new treatment to market is an immense challenge. The path from lab discovery to real-world impact is marked by regulatory hurdles, cost barriers, and the need for data that speaks to actual patient outcomes. Thanks to IQVIA's data insights, we’re able to better understand the depth of these challenges and the systems that both enable and hinder access to groundbreaking therapies : 🌍 Regulatory Complexity: Bringing a treatment to patients isn’t just about proving effectiveness; it’s about navigating an intense regulatory landscape. Each new therapy faces a rigorous approval process, with multiple checkpoints to verify safety, efficacy, and compliance with standards. This journey takes time, substantial resources, and resilience. For patients waiting on innovative solutions, this journey can feel far too long. 🌍 The Rising Cost of Care: Healthcare affordability is a growing challenge. As therapy costs climb, patients, payers, and policymakers are all faced with the reality of balancing access and sustainability. Whether it’s a cutting-edge cancer therapy or a chronic disease medication, understanding and addressing cost burdens is central to making healthcare accessible. IQVIA’s insights show the trends, but they also highlight a pressing need: affordability solutions that don’t compromise quality. 🌍 Resource Utilization and Health Outcomes: In healthcare, understanding treatment utilization patterns reveals a lot about system efficiency and patient access. IQVIA’s data spans everything from prescription trends and mental health needs to hospital admissions. Insights like these are essential for predicting how future demands can be met and what adjustments health systems might need to make to stay sustainable. For instance, data on prescription costs can guide healthcare providers and stakeholders in managing resources for better patient outcomes. These insights are not just about numbers; they represent real people, real challenges, and real needs in the health landscape. Moving forward, this evidence helps to shape policies, guide investment in innovative solutions, and design a healthcare system that doesn’t just meet today’s needs but anticipates tomorrow’s challenges. Thank you to IQVIA for shining a light on the complexities of healthcare today and for showing how real-world data can help bridge the gap between innovation and accessible care. Let’s keep pushing for a future with Enosium Life Science, where life-changing treatments reach patients faster and with fewer barriers. Herve Lilliu Stephane Roze Gabriel MARTIN Vyoo Agency Inbeeo EFPIA - European Federation of Pharmaceutical Industries and Associations France Biotech https://lnkd.in/dkjUvZJb

🚀 Is Your Medtech Company Among the Haves or the Have-Nots ? In a world where medtech innovation can make or break a company, the recent trends reveal a striking divide: since 2019, the top value creators have skyrocketed past the S&P 500, while many others are left scrambling to keep up. This gap isn’t just numbers on a page it’s a wake-up call for an industry that must evolve or risk being left behind. Key Insights from McKinsey & Company: 🔍 Top-Performers Leading the Charge: Most of the growth in medtech over the past two years has been driven by the top-decile companies, which share a common success profile characterized by: - Above-average industry growth - Relentless focus on quality - Robust innovation pipelines - Rising profit margins - Steady levels of free cash flow 💡 Prioritizing Innovation Productivity: As R&D costs have surged over the past 15 years, top medtech companies have committed to practices that enhance innovation productivity. They’re adopting digital tools and agile quality management systems to streamline processes and foster continuous improvement. This shift can lead to a 20% reduction in development time, alongside lower costs. 📊 Data-Driven Management: By defining and tracking key performance indicators (KPIs), top performers illuminate the R&D “black box,” allowing for better monitoring and optimization of productivity and cycle times. This approach fosters accountability and keeps teams focused on short-term milestones. 📈 Clinical Excellence: The demand for clinical data now extends across the board. Leading medtech firms are taking cues from the pharmaceutical industry, leveraging analytical tools to enhance trial execution and oversight. 📅 Active Portfolio Shaping: 2024 is shaping up to be a record year for acquisitions in medtech, with leading companies making 3.5 times more acquisitions than their peers since 2019. This trend underscores the strategic moves top performers are making to continuously reshape their portfolios. As we navigate this dynamic landscape, the question remains: how can other companies in the medtech space adapt these strategies to close the gap and drive their own value creation? France Biotech  Antoine Bassel Amer https://lnkd.in/eQ7RTjvS

🌍 Is Europe Losing Its Edge in Clinical Trials? Europe has long been at the forefront of clinical trials, providing patients access to cutting-edge treatments and driving billions in economic growth. But here’s the reality check: Europe’s share of global clinical trials has plummeted from 25% in 2013 to just 19% today. In stark contrast, China has doubled its share during the same period, now holding 18% of trials. With this shift, the pressing question is, can Europe keep up? This decline is particularly concerning as regions like Asia, especially China, gain momentum. Factors such as streamlined regulatory processes, robust funding, and access to large patient populations have made Asia an increasingly attractive hub for clinical trials. Notably, Europe has seen a significant decrease in phase 1 and cell and gene therapy trials, resulting in 60,000 fewer patients accessing trials within the European Economic Area (EEA) last year, according to a study by IQVIA and the EFPIA - European Federation of Pharmaceutical Industries and Associations. Despite policy efforts like the EU Clinical Trials Regulation (CTR), which aims to harmonize and simplify trial processes across member states, Europe continues to face persistent challenges. Complex regulatory requirements, slow patient recruitment, and limited access to data create delays, especially in critical areas such as oncology and neurology. Meanwhile, Spain has emerged as a standout performer, surpassing Germany in trial activity, thanks to proactive policies and effective collaboration across sectors. As Europe navigates these hurdles, what steps can be taken to secure its position as a leader in clinical trials? Can it overcome these barriers and maintain its competitive edge in the global market? 👉 At Enosium Life Science, we are committed to supporting the advancement of clinical trials in Europe, helping life sciences companies overcome regulatory, operational, and market access challenges to bring innovative therapies to patients faster. Leem EUCROF France Biotech https://lnkd.in/eYmJuizS 

📺 Dr Antoine Amer, Fondateur et Président d'Enosium Life Science, est l'invité de l'émission Check up Santé sur BFM Business, animée par Fabien GUEZ ! 👉 Fondé en janvier 2024, le groupe Enosium Life Science s’illustre par son modèle unique de groupement de services scientifiques pour les industries de santé en Europe. 🔬 Enosium propose une expertise complète : recherche clinique, affaires réglementaires, médical, marketing et accès au marché ainsi que la valorisation médico-économique des produits de santé 💡 Les enjeux de l’innovation médicale : 📈 Plus de 6000 nouvelles molécules en études cliniques et un coût de développement dépassant désormais 2 milliards d'euros par médicament innovant 💊 Plus de 50 nouveaux médicaments arrivent chaque année sur le marché, dont près de 40 % représentent de nouvelles classes thérapeutiques (datas de 2023) ⚠️ Cependant, certains défis demeurent ⏳ En Europe, les délais d’accès réel des patients aux nouveaux traitements innovants sont de plus de 500 jours après l’autorisation de mise sur le marché 👎 Moins de 20% des études cliniques mondiales sont réalisées en Europe, ce taux est en baisse chaque année. 👵👴 D'ici 2030, 25 % de la population européenne aura plus de 65 ans, avec des besoins de santé grandissants. Grâce au soutien et à l’accompagnement d'#otium, Enosium life science ambitionne de devenir un leader européen dans les services à la santé dans les cinq prochaines années #Santé #Innovation #CheckUpSanté #EnosiumLifeScience #AntoineAmer #IndustriePharmaceutique #AccèsAuxSoins #Leadership #Vieillissement #InnovationMédicale #francebiotech Otium Gabriel MARTIN Thibault Wirth Basile Paul-Petit Maxime de Varine-Bohan François Durvye Michael S Levy Stephane Roze Herve Lilliu Bertrand Tehard Amandine Vincent Julie Chevalier Camille Rémy Joelle Dagher, PhD

📺 Dr Antoine Amer, Fondateur et Président d'Enosium Life Science, est l'invité de l'émission Check up Santé sur BFM Business, animée par Fabien GUEZ ! 👉 Fondé en janvier 2024, le groupe Enosium Life Science s’illustre par son modèle unique de groupement de services scientifiques pour les industries de santé en Europe. 🔬 Enosium propose une expertise complète : recherche clinique, affaires réglementaires, médical, marketing et accès au marché ainsi que la valorisation médico-économique des produits de santé 💡 Les enjeux de l’innovation médicale : 📈 Plus de 6000 nouvelles molécules en études cliniques et un coût de développement dépassant désormais 2 milliards d'euros par médicament innovant 💊 Plus de 50 nouveaux médicaments arrivent chaque année sur le marché, dont près de 40 % représentent de nouvelles classes thérapeutiques (datas de 2023) ⚠️ Cependant, certains défis demeurent ⏳ En Europe, les délais d’accès réel des patients aux nouveaux traitements innovants sont de plus de 500 jours après l’autorisation de mise sur le marché 👎 Moins de 20% des études cliniques mondiales sont réalisées en Europe, ce taux est en baisse chaque année. 👵👴 D'ici 2030, 25 % de la population européenne aura plus de 65 ans, avec des besoins de santé grandissants. Grâce au soutien et à l’accompagnement d'#otium, Enosium life science ambitionne de devenir un leader européen dans les services à la santé dans les cinq prochaines années #Santé #Innovation #CheckUpSanté #EnosiumLifeScience #AntoineAmer #IndustriePharmaceutique #AccèsAuxSoins #Leadership #Vieillissement #InnovationMédicale #francebiotech Otium Gabriel MARTIN Thibault Wirth Basile Paul-Petit Maxime de Varine-Bohan François Durvye Michael S Levy Stephane Roze Herve Lilliu Bertrand Tehard Amandine Vincent Julie Chevalier Camille Rémy Joelle Dagher, PhD